Comparative evaluation of experimental challenge by intraperitoneal injection and cohabitation of Atlantic salmon ( Salmo salar L) after vaccination against Piscirickettsia salmonis (EM90‐like)

• Published in: Journal of Fish Diseases
• Main Authors: Meza, Karla, Inami, Makoto, Dalum, Alf S., Lund, Hege, Bjelland, Ane M., Sørum, Henning, Løvoll, Marie
• Other Authors: Norges Forskningsråd
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2019
• Subjects: Atlantic salmon; Salmo salar
• Online Access: http://dx.doi.org/10.1111/jfd.13091; https://onlinelibrary.wiley.com/doi/pdf/10.1111/jfd.13091; https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jfd.13091

Abstract The Chilean aquaculture has been challenged for years by piscirickettsiosis. A common prophylactic measurement to try to reduce the impact from this disease is vaccination, but the development of vaccines that induce satisfactory protection of the fish in the field has so far not been successful. Experimental challenge models are used to test vaccine efficacy. The aim of this study was to evaluate the performance of experimental vaccines after challenge by the two most widely used challenge routes, intraperitoneal injection and cohabitation. A total of 1,120 Atlantic salmon were vaccinated with non‐commercial experimental vaccines with increasing amounts of an inactivated Piscirickettsia salmonis EM90‐like isolate. Differences in mortality, macroscopic and microscopic pathological changes, bacterial load and immune gene expression were compared after challenge by different routes. The results revealed a similar progression of the diseases after challenge by both routes and no gross differences reflecting the efficacy of the vaccines could be identified. The analysis of the immune genes suggests a possible suppression of the cellular immunity by CD8 T cell and with this stimulation of bacterial survival and replication. Comparative studies of experimental challenge models are valuable with regard to identifying the best model to mimic real‐life conditions and vaccines’ performance.